2021
The complete story of less than complete responses: The evolution and application of acute myeloid leukemia clinical responses
Shallis RM, Pollyea DA, Zeidan AM. The complete story of less than complete responses: The evolution and application of acute myeloid leukemia clinical responses. Blood Reviews 2021, 48: 100806. PMID: 33531169, DOI: 10.1016/j.blre.2021.100806.Peer-Reviewed Original ResearchConceptsComplete remissionAcute myeloid leukemiaClinical benefitRate of CRMeasurable residual disease assessmentIncomplete platelet recoveryNon-intensive therapyPartial hematologic recoveryResidual disease assessmentFuture clinical trialsPost-therapy outcomesClinical responseHematologic recoveryOlder patientsComplete responseIntensive therapyStringent response criteriaPlatelet recoveryTherapeutic responseClinical trialsMyeloid leukemiaClinical valueNew therapiesMRD techniquesResponse criteria
2019
Molecular Measurable Residual Disease Testing of Blood During AML Cytotoxic Therapy for Early Prediction of Clinical Response
Wong H, Sung A, Lindblad K, Sheela S, Roloff G, Rizzieri D, Goswami M, Mulé M, Ramos N, Tang J, Thompson J, DeStefano C, Romero K, Dillon L, Kim D, Lai C, Hourigan C. Molecular Measurable Residual Disease Testing of Blood During AML Cytotoxic Therapy for Early Prediction of Clinical Response. Frontiers In Oncology 2019, 8: 669. PMID: 30697529, PMCID: PMC6341003, DOI: 10.3389/fonc.2018.00669.Peer-Reviewed Original ResearchAcute myeloid leukemiaMeasurable residual diseaseCytotoxic therapyQuantitative real-time PCRDay 1Measurable residual disease assessmentMeasurable residual disease testingPredictive of clinical responseMedian age of subjectsDay 4Adult AML patientsNon-synonymous variantsWild-type sequenceNext generation sequencingVariant allele frequencyAge of subjectsTesting of bloodResidual diseaseInduction therapyCytotoxic chemotherapyIntensive chemotherapyVariant burdenAML patientsClinical responseLeukemic clone
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply